NEW YORK, NY / ACCESSWIRE / June 30, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Class Period: December 30, 2019 – April 22, 2022
Lead Plaintiff Deadline: July 12, 2022
The AXSM lawsuit alleges that throughout the class period, Axsome Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome’s chemistry, manufacturing, and control (“CMC”) practices were deficient with respect to AXS-07, the Company’s medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application (“NDA”) on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration (“FDA”) reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in AXSM: https://www.kleinstocklaw.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?id=29429&from=1
Apyx Medical Corporation (NASDAQ:APYX)
Class Period: May 12, 2021 – March 11, 2022
Lead Plaintiff Deadline: August 5, 2022
The complaint alleges that during the class period Apyx Medical Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) a significant number of Apyx’s Advanced Energy products were used for off-label indications; (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events; (3) as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) as a result of the foregoing, the Company’s financial results would be adversely impacted; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in APYX: https://www.kleinstocklaw.com/pslra-1/apyx-medical-corporation-loss-submission-form-2?id=29429&from=1
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
Class Period: May 28, 2021 – May 24, 2022
Lead Plaintiff Deadline: August 5, 2022
During the class period, Verrica Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced a bulk solution for the Company’s lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in VRCA: https://www.kleinstocklaw.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?id=29429&from=1
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/707211/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-AXSM-APYX-and-VRCA
